Moreover, the synchronous expression of both EGFR and HER2 occurs in approximately 10-50 % of NSCLC patients and is also prognostic for increased recurrence risk and decreased overall survival [8-10]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.